In Brief: Merck vaccine research
Executive Summary
Merck vaccine research: Hepatitis A/hepatitis B combination vaccine development is discontinued, the company's annual report states. "An evaluation of the marketplace indicated the need for this particular vaccine was unwarranted," the report explains. Merck markets the hepatitis A vaccine Vaqta and the hepatitis B vaccine Recombivax HB. "Merck has also delayed development of a pneumococcal conjugate vaccine to focus its resources on other vaccine opportunities," according to the annual report...